TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Baseline Crohn's Disease Activity Index (CDAI) 250-400, inclusive~* Crohn's disease of at least 3 months duration, with colitis, ileitis, or ileocolitis, confirmed by radiography and/or endoscopy~* Patients receiving medications for CD must be on stable doses entering the study~* Any CD medication which has been discontinued must have been discontinued at least 4 weeks prior to screening, with the exception of infliximab, which must have been discontinued at least 8 weeks prior to screening~Exclusion Criteria~* Patients with any ostomy or extensive bowel resection~* Current evidence of bowel obstruction or history within the preceding six months as confirmed by radiography, endoscopy, or surgery~* Patients with stool examination positive for enteric pathogens, pathogenic ova or parasites, or Clostridium difficile toxin~* Treatment with any other experimental therapeutics within the last 4 weeks before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semapimod 60 mg (Type: EXPERIMENTAL): Semapimod 60 mg IV x 5 days
- Semapimod IV 30 mg (Type: EXPERIMENTAL): Semapimod IV 30 mg x 5 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo IV x 3 or 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Electrical Resistance of Different Tissues on the Outer Surface of the Heart

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All adult patients undergoing elective cardiac surgery for coronary artery disease (with or without normal heart function) or valvular disease (with normal heart function) at the Hospital of the University of Pennsylvania under the direction of Y. Joseph Woo MD will be eligible.~Exclusion Criteria:~* Patients undergoing emergent surgery and patients with idiopathic cardiomyopathy, infiltrative cardiomyopathies and hypertrophic cardiomyopathies will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females~2. Over 18 years of age~3. Confirmed written informed consent.~4. Acute decompensated heart failure based on physicians assessment and requiring treatment as per standard emergency department protocols for this condition.~5. Requirement for intravenous therapy of HF, e.g. diuretic, vasodilator.~6. COAD based on physician's assessment and requiring treatment as per standard emergency department protocols for this condition. Must have at least 2 of the following criteria:~   * history of smoking \> 20 pack years,~  * prior history of PFTs within last 1 year consistent with COAD,~  * history of chronic cough and sputum production,~  * progressive dyspnea, episodes of acute bronchitis over at least 2 yrs~Exclusion Criteria:~1. Women lactating, pregnant or of childbearing potential not using 2 reliable contraceptive methods.~2. Patients who had received an investigational new drug within the last 4 weeks.~3. Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.~4. SBP \<90mmHg~5. Creatinine \>0.25mmol/L~6. Sp02 \< 80% on supplemental oxygen or known cor pulmonale with TR

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Nesiritide
- B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life Assessment of Patients Receiving Treatment for Esophageal Cancer [Companion to CALGB-9781]

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
1. Patients with histologically documented untreated squamous cell carcinoma or adenocarcinoma of the thoracic esophagus (below 20 cm) or gastroesophageal junction and with less than 2cmdistal spread into the gastric cardia eligible for C9781.~2. There could be no evidence of distant metastatic disease by history and physical examination; upper endoscopy with biopsy, computed tomography (CT) of the chest and upper abdomen, and pulmonary function studies were all required.~3. Tumors had to be considered surgically resectable (T1-3, NX), including regional thoracic lymph node (N1) metastases.~4. Patients with supraclavicular lymph nodes measuring ≤1.5 cm by CT (not palpable) were eligible, as were patients with lymph node metastases to levels 15 to 20 (predominantly celiac axis and paracardial nodes) ≤ 1.5 cm by CT.~5. Patients could not have previously received chemotherapy or radiation therapy for this tumor or any radiation therapy that would overlap the radiation fields required for this malignancy. Patients with previous malignancies were eligible if more than 5 years had elapsed from diagnosis without evidence of tumor recurrence.~6. There could be no other serious illness that would limit survival to less than 2 years, or psychiatric condition that would prevent compliance with treatment or informed consent.~7. Patients with uncontrolled or severe cardiovascular disease, pulmonary disease, or active infections were excluded, as were pregnant patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Xen Implantation on the Aqueous Humor Proteome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female of any racial or ethnic origin, 18 years or older~* Able to provide written informed consent.~* Scheduled to undergo Xen implantation for open angle glaucoma or already has an aqueous shunt~Exclusion Criteria:~* History of conjunctivitis or any ocular infection within the past 3 weeks.~* Any active inflammation of the cornea or the anterior chamber (uveitis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Xen (Type: None): Patients treated with a Xen microstent for glaucoma.
- Aqueous shunt (Type: None): Patients treated with an aqueous shunt for glaucoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥18 years)~* Signed informed consent~* Subjects affiliated with an appropriate social security system~* Body mass index above 30 kg/m2 and~* Pathological waist circumference according to criteria of NCEP ATPIII (men : 94 cm and women : 80 cm)~Exclusion Criteria:~* Pregnancy~* Sepsis~* Recent surgery (less than 30 days)~* Any recent severe acute conditions requiring hospitalisation (less than 30 days)~* Recent use (\< 7 days) of oral steroids, inhaled, dermal, collyrium, infiltration~* Long-term oral corticosteroids~* Nicotinic substitute or per os licorice in 2 weeks before the inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Salivary cortisol (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Both genders are eligible for study~2. Age 18 years and older~3. Able to provide written, informed consent~4. Confirmed diagnosis of severe CDAD as defined above~Exclusion Criteria:~(If any of the following apply, the subject MUST NOT enter the study):~1. Pregnant or lactating women~2. Need for prolonged antibiotics for other cause~3. Other known etiology for diarrhea, or clinical infection with other known enteric pathogens~4. Active, chronic conditions such as: Inflammatory bowel disease, Crohn's disease, Short bowel syndrome, Ulcerative or ischemic colitis~5. Laxatives or motility-altering drugs within 12 hours of enrolment~6. Clinically unstable. Hemodynamic instability defined as hypotension (mean arterial pressure \< 60) not responsive to fluids.~7. Any condition that, in the opinion of the investigator, would preclude safe participation in the trial or compromise the quality of the data obtained.~8. Immune suppression, HIV, hematological or solid malignancy (chemotherapy in the past 3 months).~9. Prior colon surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fecal microbiota transplant (Type: EXPERIMENTAL): fecal microbiota transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical~1. Patients with angina and documented ischemia or patients with documented silent ischemia~2. Patients who are eligible and has been successfully applied for DES implantation~3. Age \>18 years~4. Signed written informed consent form prior to study entry~2. Angiographic~1. De novo lesion or restenotic lesions~2. Percent diameter stenosis ≥50%~3. Reference vessel size 2.5 mm by visual estimation~Exclusion Criteria:~1. History of bleeding diathesis or coagulopathy (e.g. current use of NSAIDs, Upper GI bleeding during the recent 6 months)~2. Pregnancy or lactation (women who have child-bearing potential)~3. Known hypersensitivity or contra-indication to contrast agent, heparin, eluted-drug of stent~4. Limited life-expectancy (less than 1 year) due to combined serious disease~5. Characteristics of lesion 1)Left main disease 2)Graft vessels~6. Hematological disease (Neutropenia \<3000/mm3, Thrombocytopenia \<100,000/mm3)~7. Hepatic dysfunction, liver enzyme (ALT and AST) elevation 3 times normal~8. Renal dysfunction, creatinine 2.0mg/dL~9. Contraindication to aspirin, clopidogrel or cilostazol~10. Stroke (ischemic or hemorrhagic) or transient ischemic attack (TIA) within 6 months.~11. Planned major surgery within the next 6 months with the need to discontinue antiplatelet therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cilostazol (Type: EXPERIMENTAL): cilostazol 100mg
- dual therapy group (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bronchoscopic Laser Ablation of Peripheral Lung Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Performance status 0-2 (Eastern Cooperative Oncology Group classification)~* Subject is considered a candidate for bronchoscopy~* Subject is considered a candidate for surgery (other lobar or sub-lobar resection) based on radiographic staging and functional evaluation~* Lung lesion that is either biopsy-proven cancer or is suspicious for cancer~* Both non-small cell lung cancer (including carcinoid tumors) and metastatic disease~* The lesions should be: =\< 3 cm, located in the outer 2/3 of the lung, and leave \>= 1 cm of tumor-free lung parenchyma between target tumor and pleura or fissure~Exclusion Criteria:~* Tumors greater than 3 cm, located in the inner 1/3 of the lung, invading a major vessel, or located \< 1 cm from the pleural or fissure~* Tumors qualified as non-resectable~* Tumors that cannot be reached bronchoscopically~* Patients declared non-surgical candidates~* Patients who are not candidates for bronchoscopy~* Patients with lung cancer who are found to have N2-3 disease~* Patient with lung metastases who are found to have any malignant mediastinal lymph node~* Patients in which the target lesion is confirmed as benign or small cell lung cancer~* Patients without a prior diagnosis of the target lesion whose diagnosis cannot be made during bronchoscopy~* Patients who have received chemotherapy within 60 days prior to bronchoscopic laser ablation~* Patients who were previously treated for the target lesion~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (bronchoscopic laser ablation, CBCT) (Type: EXPERIMENTAL): Patients undergo bronchoscopic laser ablation following standard bronchoscopy and endobronchial ultrasound. Patients also undergo CBCT before and after laser ablation. 48-72 hours after the procedure, patients undergo standard surgical resection of the lung tumor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Double Blinded Randomized Control Trial of Types of IVF in Children With DKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 0 and 18 years~2. Diagnosis of DKA:~   1. Venous pH less than 7.25~  2. Ketonuria as confirmed on urine point-of-care testing or urinalysis~  3. Hyperglycemia (Serum glucose \> 200 mg/dl)~  4. Serum bicarbonate \<15 mmol/L~3. PICU admission~Exclusion Criteria:~1. Age \> 18 Years~2. Physician discretion~3. Septic or hypovolemic shock~4. Signs of life-threatening cerebral edema or multi-organ failure upon presentation to the emergency room or pediatric intensive care unit~5. Enrollment time more than 1 hr since arrival to emergency room or PICU~6. Pregnancy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: PLACEBO_COMPARATOR): Intervention: intravenous solutions containing only normal saline as the primary base during the entire treatment of diabetic ketoacidosis.
- Lactated Ringers (Type: EXPERIMENTAL): Intervention: intravenous solutions containing only lactated ringers as the primary base during the entire treatment of diabetic ketoacidosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pain Treatment After Total Knee Replacement - Continuous Epidural Versus Intravenous Patient Controlled Analgesia With Morphine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Age: 55 to 85 years~* Osteoarthritis~* Primary unilateral total knee replacement~* American Society of Anesthesiologists (ASA) I-III~* Successful spinal epidural anesthesia for surgery~Exclusion Criteria:~* Any cause for knee replacement other than osteoarthritis~* Total knee revision (re-do)~* Any contraindication for regional anesthesia~* Abnormal coagulation studies~* Thrombocytopenia less than 100,000/cc~* Chronic renal failure (creatinine \[cr\] \< 1.8)~* Neurological disease involving lower extremities~* Major surgery during the last 2 weeks pre-operatively~* Current or past drug or alcohol abuse~* Allergy to study medications~* Post-operative bleeding over 2000 cc/24 hours~* Postdural puncture headache after anesthesia performance

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Enrolled on protocol IBCSG-1-98~  * Currently receiving (i.e., have not yet completed) 5 years of treatment with tamoxifen or letrozole and expected to receive ≥ 6 months of additional treatment on protocol IBCSG-1-98~* No recurrent breast cancer or second primary cancer~* No known bone disease (including osteomalacia or osteogenesis imperfecta)~* Hormone receptor status~  * Estrogen and/or progesterone receptor positive tumor~PATIENT CHARACTERISTICS:~* Female~* Postmenopausal~* No uncontrolled thyroid or parathyroid disease, Cushing's disease, or other pituitary diseases~* No malabsorption syndrome or clinically relevant vitamin D deficiency~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 1 year since prior and no concurrent anticonvulsants~* More than 6 months since prior and no concurrent corticosteroids at doses \> the equivalent of 5 mg/day of prednisone for \> 2 weeks total~* No prior or concurrent sodium fluoride at daily doses ≥ 5 mg/day for \> 1 month~* More than 12 months since prior and no concurrent anabolic steroids~* More than 6 months since any prior drug for the prevention of osteoporosis (excluding calcium or cholecalciferol \[vitamin D\])~* Concurrent warfarin allowed provided duration of treatment is no more than 4 weeks

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tamoxifen and no bone fracture (Type: EXPERIMENTAL): Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have not had a bone fracture.
- Letrozole and no bone fracture (Type: EXPERIMENTAL): Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have not had a bone fracture.
- Tamoxifen and bone fracture (Type: EXPERIMENTAL): Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have had a bone fracture.
- Letrozole and bone fracture (Type: EXPERIMENTAL): Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have had a bone fracture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 18 or older who are referred for elective cardiac CT examination for evaluation of coronary artery disease~Exclusion Criteria:~* hemodynamic instability~* history of anaphylactic contrast reaction~* inability of following breath hold instructions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cardiogoniometry and ECG Assessment (Type: OTHER): The same patient will undergo both advanced ECG assessment using cardiogoniometry and standard ECG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reinnervation of Facial Muscles After Lengthening Temporalis Myoplasty

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patient who were operated for a facial paralysis by the lengthening temporalis myoplasty procedure in the University Hospital of Caen and who present signs of contraction of the facial muscles on the plasy side after the procedure.~Exclusion Criteria:~* Patient with contraindications to the injection of lidocaine~* Patient treated with beta-blocker~* Patient on anti-coagulants~* Pathology cause of facial paralysis evolving~* Pregnant or lactating~* Patient incapacitated adult~* Patient undergoing another study at the same time

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Neurotized facial muscle patients (Type: EXPERIMENTAL): injection of 1% lidocaine, 2mL for facial nerve block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility